Ambitious Bio raises $6M seed to map human proteins for AI
What's the deal? Cambridge-based Ambitious BioDealroom has a profile for this one. Try Dealroom → has raised a $6 million seed round, announced September 22 — its first disclosed funding since emerging from stealth in June. The company declined to name its investors.
What's the endgame? The round coincided with the launch of Corpus, a protein atlas tracking protein presence and abundance across healthy human tissues. Ambitious says Corpus expands the inventory of detected proteins by a median of 56% per tissue compared with the Human Protein Atlas, the field's most widely referenced public database.
In 181 head-to-head comparisons with major public references, adding Corpus data raised detected protein counts every time, with typical gains of 28% to 78% per matched tissue, according to the company.
Why it matters: Among 973 proteins pursued as drug targets without an approved medicine, the Human Protein Atlas detected no healthy tissue expression for 19% — while Corpus reported finding it. Knowing where a protein naturally appears helps researchers anticipate side effects and identify which patients a drug might help or harm.
Founder and chief executive officer Elizabeth Hudson previously served as chief technology officer at Omega FundsDealroom has a profile for this one. Try Dealroom → and led data engineering at warehouse automation firm Symbotic. She also serves as an intelligence officer in the US Navy Reserve.
Ambitious frames its mission as building "a systematic record of human biology for AI," drawing an analogy to Common CrawlDealroom has a profile for this one. Try Dealroom →, the web dataset used to train large language models. Board member Jeff Martin added: "The lesson Apple demonstrated most clearly is that the most consequential products become foundations for entirely new industries."
What's next? Ambitious plans to extend Corpus from healthy to diseased tissue, add molecular data beyond proteins, and eventually cover other organisms. It disclosed no commercial customers.
The signal: The $6 million sits in the top 10% of US health seed rounds, a notable figure in a capital-intensive space. Proteomics has consolidated fast — Thermo Fisher acquired OlinkDealroom has a profile for this one. Try Dealroom → in 2024, and Standard BioTools merged with SomaLogic — while academic efforts like the UK Biobank's 500,000-participant plasma study, due to begin releasing data in 2026, press ahead. Ambitious is betting its broader coverage can turn protein mapping into infrastructure for biological AI.
Read more: founderland.ai
Image credit: Enzymlogic
